Publications

MDC1 Directly Binds Phosphorylated Histone H2AX to Regulate Cellular Responses to DNA Double-Strand Breaks (DOI:10.1016/j.cell.2005.09.038)

Authors: M Stucki, JA Clapperton, D Mohammad, MB Yaffe, SJ Smerdon, SP Jackson

Research group: Jackson Group

E-pub date: 24 Mar 2006

Journal name: Cell

Structure of an Xrcc4-DNA ligase IV yeast ortholog complex reveals a novel BRCT interaction mode.

Authors: AS Doré, N Furnham, OR Davies, BL Sibanda, DY Chirgadze, SP Jackson, L Pel...

Research group: Jackson Group

E-pub date: 7 Mar 2006

Journal name: DNA Repair (Amst)

Macroscopic 2D networks self-assembled from nanometer-sized protein/DNA complexes.

Authors: M Manzanera, DJ Frankel, H Li, D Zhou, A Bruckbauer, P Kreutzmann, JM Black...

Research group: Microscopy

E-pub date: 1 Mar 2006

Journal name: Nano Lett

Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.

Authors: LD McPhail, DJO McIntyre, C Ludwig, P Kestell, JR Griffiths, LR Kelland, SP...

Research group: Pre-clinical imaging

E-pub date: 1 Mar 2006

Journal name: Neoplasia

Erratum: Corrigendum: Probing tumor phenotypes using stable and regulated synthetic microRNA precursors

Authors: RA Dickins, MT Hemann, JT Zilfou, DR Simpson, I Ibarra, GJ Hannon, SW Lowe

Research group: Hannon Group

E-pub date: 1 Mar 2006

Journal name: Nature Genetics

Bex2 identifies a novel subtype of breast cancer associated with estrogen-response and NGF/NF-KB pathway

Authors: A Naderi, Teschendorff, J Beigel, M Cariati, I Ellis, J Brenton, C Caldas

Research group: Brenton Group

E-pub date: 1 Mar 2006

Journal name: European Journal of Cancer Supplements

Robust identification of novel prognostic gene-signatures in breast cancer

Authors: A Naderi, AE Teschendorff, NL Barbosa-Morais, JFR Robertson, IO Ellis, JD B...

Research group: Brenton Group

E-pub date: 1 Mar 2006

Journal name: European Journal of Cancer Supplements

High-grade glioma: can we teach an old dogma new tricks?

Authors: RJ Gilbertson

Research group: Gilbertson Group

E-pub date: 1 Mar 2006

Journal name: Cancer Cell

Filters

Research Groups

Core Facilities

Start date

End date

MDC1 Directly Binds Phosphorylated Histone H2AX to Regulate Cellular Responses to DNA Double-Strand Breaks (DOI:10.1016/j.cell.2005.09.038)

Structure of an Xrcc4-DNA ligase IV yeast ortholog complex reveals a novel BRCT interaction mode.

Macroscopic 2D networks self-assembled from nanometer-sized protein/DNA complexes.

Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.

Erratum: Corrigendum: Probing tumor phenotypes using stable and regulated synthetic microRNA precursors

Bex2 identifies a novel subtype of breast cancer associated with estrogen-response and NGF/NF-KB pathway

Robust identification of novel prognostic gene-signatures in breast cancer

High-grade glioma: can we teach an old dogma new tricks?

Themes

Filters

Research Groups

Core Facilities

Start date

End date

MDC1 Directly Binds Phosphorylated Histone H2AX to Regulate Cellular Responses to DNA Double-Strand Breaks (DOI:10.1016/j.cell.2005.09.038)

Structure of an Xrcc4-DNA ligase IV yeast ortholog complex reveals a novel BRCT interaction mode.

Macroscopic 2D networks self-assembled from nanometer-sized protein/DNA complexes.

Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.

Erratum: Corrigendum: Probing tumor phenotypes using stable and regulated synthetic microRNA precursors

Bex2 identifies a novel subtype of breast cancer associated with estrogen-response and NGF/NF-KB pathway

Robust identification of novel prognostic gene-signatures in breast cancer

High-grade glioma: can we teach an old dogma new tricks?